Immunome Inc. (IMNM) — 8-K Filings

8-K Filings (25)

• Immunome Inc. Files 8-K: Other Events & Exhibits — Dec 17, 2025 Risk: low
  Immunome Inc. filed an 8-K on December 17, 2025, reporting on events that occurred on December 16, 2025. The filing is primarily an "Other Events" and "Financia
• 8-K Filing — Dec 15, 2025
• Immunome Inc. Files 8-K on Shareholder Vote Matters — Jun 11, 2025 Risk: low
  Immunome Inc. filed an 8-K on June 11, 2025, reporting on matters submitted to a vote of its security holders on June 10, 2025. The filing details the company's
• Immunome Inc. Files 8-K on Operations and Financials — May 12, 2025 Risk: low
  Immunome, Inc. filed an 8-K on May 12, 2025, reporting on events that occurred on May 8, 2025. The filing pertains to results of operations, financial condition
• Immunome Inc. Files 8-K on Financials — Mar 19, 2025 Risk: low
  Immunome, Inc. filed an 8-K on March 19, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
• Immunome Inc. Files 8-K Report — Jan 30, 2025 Risk: low
  Immunome Inc. filed an 8-K report on January 30, 2025, detailing events that occurred on January 29, 2025. The filing is categorized under 'Other Events' and 'F
• Immunome Inc. Files 8-K on Operations and Other Events — Jan 29, 2025 Risk: low
  Immunome, Inc. filed an 8-K on January 29, 2025, reporting on its Results of Operations and Financial Condition, as well as Other Events. The filing details the
• Immunome Inc. Reports Board and Compensation Changes — Jan 23, 2025 Risk: low
  Immunome Inc. announced on January 21, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of dire
• Immunome Inc. Files 8-K on Financials and Operations — Nov 13, 2024 Risk: low
  Immunome, Inc. filed an 8-K report on November 13, 2024, to disclose information regarding its results of operations and financial condition, as well as financi
• Immunome Inc. Reports Material Agreements & Asset Changes — Oct 29, 2024 Risk: medium
  Immunome, Inc. filed an 8-K on October 29, 2024, reporting events as of October 25, 2024. The filing indicates the entry into and termination of material defini
• Immunome to Combine with ROME Therapeutics — Oct 8, 2024 Risk: medium
  Immunome Inc. announced on October 3, 2024, that it entered into a definitive agreement for a business combination with ROME Therapeutics Ltd. The transaction i
• Immunome Inc. Files 8-K on Operations and Financials — Aug 12, 2024 Risk: low
  Immunome, Inc. filed an 8-K on August 12, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhi
• Immunome Inc. Reports on Security Holder Vote — Jun 13, 2024 Risk: low
  Immunome, Inc. filed an 8-K on June 13, 2024, reporting on matters submitted to a vote of its security holders on June 12, 2024. The filing details the company'
• Immunome Inc. Files 8-K on Operations and Financials — May 14, 2024 Risk: low
  Immunome, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The f
• Immunome Appoints New CMO and Board Members — Apr 30, 2024 Risk: low
  Immunome, Inc. announced on April 24, 2024, the appointment of Dr. P. Ann S. Smith as Chief Medical Officer and the election of Dr. Smith and Dr. Jonathan M. Ro
• Immunome Inc. Appoints New Chairman, Adjusts Executive Compensation — Apr 25, 2024 Risk: medium
  Immunome, Inc. announced on April 25, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Jonathan M. Rothberg has been appoin
• Immunome Inc. Files 8-K on Operations and Financials — Mar 28, 2024 Risk: low
  Immunome, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and
• Immunome Inc. Files 8-K: Material Agreement, Asset Deal, Equity Sales — Mar 26, 2024 Risk: medium
  Immunome, Inc. announced on March 25, 2024, that it has entered into a material definitive agreement. The company also reported the completion of an acquisition
• Immunome 8-K Filed: Event Details Not Included in Provided Text — Feb 14, 2024 Risk: medium
  The provided text is the header and initial boilerplate of an 8-K filing by Immunome, Inc. (CIK: 0001472012), filed on February 14, 2024, reporting an event on
• Immunome Files 8-K on Financials and Other Events — Feb 13, 2024 Risk: low
  Immunome, Inc. filed a Form 8-K on February 13, 2024, to report on its Results of Operations and Financial Condition and Other Events. The company, incorporated
• Immunome Sells New Equity, Raises Capital — Feb 6, 2024
  Immunome, Inc. filed an 8-K on February 6, 2024, reporting a material definitive agreement and unregistered sales of equity securities that occurred on February
• Immunome 8-K: Leadership/Compensation Changes Reported Jan 31, 2024 — Feb 1, 2024
  Immunome, Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 31, 2024. This filing indicates a change related to the 'Departure
• Immunome 8-K Signals Major Corporate Event, Broad Shareholder Comms — Jan 11, 2024
  Immunome, Inc. filed an 8-K on January 11, 2024, to disclose that it is simultaneously satisfying filing obligations under Rule 425 of the Securities Act, Rule
• Immunome Sells Equity Securities in Unregistered Offering — Jan 8, 2024
  Immunome, Inc. entered into a material definitive agreement on January 5, 2024, involving the unregistered sale of equity securities. This filing indicates that
• Immunome 8-K Signals Executive/Comp Changes on Jan 2, 2024 — Jan 2, 2024
  Immunome, Inc. filed an 8-K on January 2, 2024, to report an event related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointmen

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX